Blog
63 Articles
Pancreatic Cancer Science—2021 in Review
As the year winds down Let’s Win provides an overall look at the highlights of 2021 in pancreatic cancer science.
Precursors to Pancreatic Cancer: Are There Any Signs to Watch Out For?
Dr. Venkata Akshintala outlines some of the precursors to pancreatic cancer that people should look out for.
Testing a PARP Inhibitor for Metastatic Pancreatic Cancer Patients with DNA Repair Mutations
Researchers are testing a PARP inhibitor that is effective for cancers in pancreatic cancer patients with DNA repair mutations.
Finding More Clues about Circulating Tumor DNA
Researcher Dr. Gehan Botrus looks at circulating tumor DNA for genetic information on a patient’s pancreatic cancer to personalize treatment.
Identifying Biomarkers for Early Detection of Pancreatic Cancer
A clinical trial for at-risk people is looking for biomarkers that can indicate pancreatic cancer is growing.
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
Chemotherapy Plus Stem Cell Infusion and Vitamins for BRCA Mutated Pancreatic Cancer
A clinical trial for pancreatic cancer patients with a BRCA mutation uses a combination of chemotherapy, vitamins, and stem cells.
Learn the Risk Factors
In the first Let’s Learn webinar, Learn the Risk Factors, experts explain how diabetes, genetic mutations, and pancreatitis impact pancreatic cancer.
A Year in Review: 2020
In March 2020, life as we knew it changed. The way we work, the way we gather, the way we each live our daily lives all felt upended, seemingly overnight. The global pandemic of COVID-19 affected everything, including cancer care and research. COVID-19 brought new risks to cancer patients, whose immune systems are compromised from […]
An Expanded Access Trial for Cancer Patients with Specific Mutations
An investigational drug is being used in an expanded access trial for advanced pancreatic and other cancer patients with specific genetic changes.
AACR Virtual Special Conference on Pancreatic Cancer: Day Two Highlights
Let’s Win and the Lustgarten Foundation present highlights of Day Two of the AACR Virtual Special Conference on Pancreatic Cancer.
AACR Virtual Special Conference on Pancreatic Cancer: Day One Highlights
Let’s Win and the Lustgarten Foundation present highlights of Day One of the AACR Virtual Special Conference on Pancreatic Cancer.
GENERATE Trial Expands Eligibility
Dr. Sapna Syngal explains the expanded eligibility standards for the GENERATE Study for genetic testing of pancreatic cancer patients and relatives.
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
Looking Back at the Year in Research: 2019
Research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.